SLE/Lupus PBMC Donors: Disease-State Portfolio and Clinical Annotation

Reviewed by Sarah Alter, Ph.D. — Scientific Affairs, OrganaBio. 15 years of immunology research spanning autoimmunity, cancer, and infectious disease. University of Miami Miller School of Medicine. Registered Patent Agent.

Systemic lupus erythematosus research requires donor material that reflects the complexity of the disease: documented disease activity at time of collection, verified clinical annotation, appropriate medication washout, and processing that preserves the phenotypic and functional characteristics of SLE-associated cell populations. Generic PBMC suppliers rarely meet all four criteria simultaneously.

OrganaBio’s SLE donor pool supports research programs across immune profiling, mechanistic studies, drug candidate screening, and biomarker development for lupus and related autoimmune indications. This page covers what clinical annotation we provide, which cell populations are available, and what to consider when selecting a disease-state PBMC supplier for SLE work.

What SLE Research Requires From Donor Material

SLE is a heterogeneous disease. Disease activity varies widely between donors and within the same donor over time. For research that depends on donor immune phenotype — as most mechanistic and translational SLE work does — the clinical metadata behind each donation matters as much as the cell counts.

Key annotation requirements for SLE research include:

• Disease activity score at time of collection. SLEDAI-2K (SLE Disease Activity Index) is the standard clinical measurement tool. Collections should document whether the donor was in active disease or clinical remission at time of draw.
• Medication washout documentation. Common SLE medications including hydroxychloroquine, mycophenolate mofetil, prednisone, and biologics (belimumab, rituximab) all affect immune cell populations and functional responses. Donors on hydroxychloroquine, which has a very long half-life, require extended washout periods for studies that need medication-naive immune profiles. OrganaBio documents current and recent medications for all disease-state donors.
• HLA typing. SLE has strong HLA associations, particularly with HLA-DR2 (DRB1*15:01) and HLA-DR3 (DRB1*03:01). For research programs investigating antigen-specific responses, HLA-typed donors with documented SLE-associated alleles are required. OrganaBio provides HLA typing for SLE donors.
• Disease duration and organ involvement documentation. Nephritis-positive SLE, neuropsychiatric SLE, and cutaneous lupus present different immune profiles. Donor annotation specifying organ involvement allows researchers to stratify collections by clinical subtype.
• Complement levels. Low C3/C4 is a common indicator of active lupus. Documentation of complement levels at time of collection provides additional context for researchers using these donors in complement-related studies.

Cell Populations Available From SLE Donors

SLE pathophysiology involves dysregulation across multiple immune compartments. The populations most relevant to current SLE research programs include:

T Helper Subsets: Th17 and Tfh

Th17 cells and their Th17.1 subset (co-expressing IFN-gamma) are among the most disease-relevant populations in SLE and among the most phenotypically sensitive to suboptimal processing conditions. Studies have documented that Th17 and Th17.1 frequency and cytokine production shift substantially in samples that experience prolonged handling before processing. For SLE research specifically, where Th17/Th17.1 ratios and function are often primary endpoints, the time from collection to processing is a meaningful experimental variable.

OrganaBio processes all disease-state leukapheresis product from SLE donors under the same receipt-to-processing standard that governs our healthy donor material. This matters for disease-state collections because the immune cells from SLE donors are not metabolically equivalent to cells from healthy donors — they arrive under inflammatory conditions that can accelerate ex vivo changes under handling stress.

B Cells and Plasmablasts

B cell dysregulation is central to SLE pathophysiology, with plasmablast expansion and loss of tolerance driving autoantibody production. SLE donors show expanded plasmablast frequencies compared to healthy controls, and these cells can be isolated from OrganaBio’s PBMC fractions for studies of B cell differentiation, autoantibody production, and BCR signaling.

Regulatory T Cells (Tregs)

Treg deficiency or dysfunction is documented in SLE, making SLE donor material relevant for programs developing Treg-based therapies or studying mechanisms of tolerance loss. OrganaBio’s SLE donors support Treg frequency and function characterization.

Plasmacytoid Dendritic Cells (pDCs)

pDCs are the primary producers of type I interferon in SLE, and the IFN signature is a core feature of active disease. Isolation of pDCs from SLE PBMCs for type I IFN pathway studies is supported by OrganaBio’s processing approach, which preserves rare cell fractions that are lost in samples processed under extended handling times.

Neutrophils and Low-Density Granulocytes

Low-density granulocytes (LDGs) co-purify with PBMCs in SLE donors and are a disease-relevant population involved in NET formation and interferon amplification. Donors with documented active disease show elevated LDG frequencies. OrganaBio’s documentation includes granulocyte content, allowing researchers to account for or isolate LDGs based on their experimental design.

Donor Annotation at OrganaBio

All SLE donors in OrganaBio’s disease-state program are annotated with the following minimum clinical data fields:

• Confirmed SLE diagnosis per ACR/EULAR criteria
• SLEDAI-2K score at or near time of collection
• Disease duration from diagnosis
• Active organ involvement (renal, neuropsychiatric, mucocutaneous, hematologic)
• Current and recent medications with washout status
• ANA titer and pattern
• Anti-dsDNA antibody status
• Complement levels (C3, C4) when available
• HLA typing
• Donor age, sex, and race/ethnicity

Post-processing product documentation includes PBMC viability, total nucleated cell count, and cell differential by flow cytometry. Post-thaw viability for OrganaBio’s disease-state donors exceeds 80% as the quality standard for released product.

Research Applications

OrganaBio’s SLE PBMC donors support a range of research applications:

• Immune phenotyping studies comparing SLE patients to healthy controls across T, B, NK, and innate immune compartments
• Drug candidate screening using primary SLE donor cells to evaluate effects on disease-relevant pathways (IFN signaling, Th17 differentiation, plasmablast formation)
• Biomarker discovery across transcriptomic, proteomic, and metabolomic platforms using annotated SLE donor samples
• Cytokine and stimulation assays characterizing disease-state immune responsiveness vs. healthy controls
• Autoantibody and B cell studies using donors with documented anti-dsDNA, anti-Sm, anti-Ro/SSA, and other SLE-associated autoantibody profiles
• Treg and immune regulation studies requiring donors with documented regulatory T cell deficiency

Selecting SLE Donors for Your Research Program

The right SLE donor selection depends on your research question. Consider the following criteria when specifying donors for your program:

Active disease vs. remission. Programs studying disease pathogenesis typically require donors with active disease (SLEDAI-2K > 4). Programs developing treatments that target specific pathways may need both active and remission donors for comparison. Some biomarker programs require samples across the full disease activity spectrum.

Medication status. Studies using functional assays or cytokine readouts should specify whether donors need to be free of immunosuppressive medications. Given hydroxychloroquine’s extended half-life (approximately 40 days to 50% reduction), studies requiring medication-naive immune responses should specify HCQ-naive or washout-documented donors explicitly.

Organ involvement. Lupus nephritis donors present different immune profiles than SLE donors without renal involvement. Specify organ involvement requirements upfront to avoid receiving donors whose clinical subtype does not match your experimental model.

Donor sex. SLE is heavily female-predominant (9:1 female to male ratio in most populations). Male SLE donors represent a minority of OrganaBio’s disease-state pool. If your program requires sex-matched comparisons or specifically requires male SLE donors, discuss availability with OrganaBio’s donor management team before finalizing your order.

Frequently Asked Questions

Are OrganaBio’s SLE PBMC donors suitable for GMP manufacturing?

No. OrganaBio’s disease-state donor materials, including SLE donors, are for research use only (RUO). They are appropriate for discovery work, drug screening, biomarker research, and mechanistic studies. For autologous cell therapy programs using lupus patient material, OrganaBio’s clinical apheresis services apply different regulatory and quality standards. If you are developing a cell therapy for SLE patients and need GMP-quality starting material from patient donors, contact OrganaBio’s clinical team to discuss program-specific requirements.

What is the post-thaw viability for SLE donor PBMCs?

OrganaBio’s quality standard for released disease-state cryopreserved PBMCs is greater than 80% post-thaw viability. SLE donors are processed under the same receipt-to-processing standards as other disease-state collections to preserve phenotypic integrity before cryopreservation.

How many SLE donors does OrganaBio have available?

Availability of SLE donors varies based on clinical annotation requirements, SLEDAI activity level, and medication status. Contact OrganaBio’s donor management team with your specific requirements to receive a current availability snapshot and lead time estimate for your program.

Can I request recurring collections from the same SLE donor?

Yes. OrganaBio supports longitudinal collection designs for SLE research, including recurring collections from the same donor across different disease activity timepoints. Longitudinal SLE donors are particularly valuable for programs studying disease flare mechanisms or treatment response over time.

Requesting SLE Donor Material

To discuss SLE donor availability, clinical annotation options, and delivery timelines for your research program, contact OrganaBio’s team. Provide a brief description of your research application and the clinical annotation fields you require, and we will identify donors in the current pool that match your program specifications.